• Arch Iran Med · Mar 2021

    Multicenter Study

    The Iranian Study of Opium and Cancer (IROPICAN): Rationale, Design, and Initial Findings.

    • Maryam Hadji, Hamideh Rashidian, Maryam Marzban, Mahin Gholipour, Ahmad Naghibzadeh-Tahami, Elham Mohebbi, Elmira Ebrahimi, Bayan Hosseini, Ali Akbar Haghdoost, Abbas Rezaianzadeh, Afarin Rahimi-Movaghar, Abdolvahab Moradi, Monireh Sadat Seyyedsalehi, Reza Shirkoohi, Hossein Poustchi, Sareh Eghtesad, Farid Najafi, Roya Safari-Faramani, Reza Alizadeh-Navaei, Ali Reza Ansari Moghadam, Mahdieh Bakhshi, Azim Nejatizadeh, Masumeh Mahmudi, Soudabeh Shahid-Sales, Saideh Ahmadi-Simab, Omid Nabavian, Paolo Boffetta, Eero Pukkala, Elisabete Weiderpass, Farin Kamangar, and Kazem Zendehdel.
    • Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland.
    • Arch Iran Med. 2021 Mar 1; 24 (3): 167176167-176.

    BackgroundThe International Agency for Research on Cancer (IARC) recently classified opium use as a Group 1 carcinogen. However, much remains to be studied on the relation between opium and cancer. We designed the Iranian Opium and Cancer (IROPICAN) study to further investigate the association of opium use and cancers of the head and neck, bladder, lung, and colon and rectum. In this paper, we describe the rationale, design, and some initial results of the IROPICAN Study.MethodsThe IROPICAN is a multi-center case-control study conducted in 10 provinces of Iran. The cases were all histologically confirmed and the controls were selected from hospital visitors who were free of cancer, were not family members or friends of the cancer patients, and were visiting the hospital for reasons other than their own ailment. The questionnaires included detailed questions on opium use (including age at initiation, duration, frequency, typical amount, and route), and potential confounders, such as tobacco use (e.g., cigarettes, nass and water-pipe), and dietary factors. Biological samples, including blood and saliva, were also collected.ResultsThe validation and pilot phases showed reasonably good validity, with sensitivities of 70% and 69% for the cases and controls, respectively, in reporting opium use. The results also showed excellent reliability, with intra-class correlation coefficients of 0.96 for ever opium use and 0.88 (95% CI: 0.80, 0.92) for regular opium use. In the main phase, we recruited 3299 cancer cases (99% response rate) and 3477 hospital visitor controls (89% response rate). The proportion of ever-use of opium was 40% among cases and 18% among controls.ConclusionThe IROPICAN study will serve as a major resource in studies addressing the effect of opium on risk of cancers of the head and neck, bladder, lung, and colon and rectum.© 2021 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.